Products & Services · Accounts Receivable

Net product revenues — Accounts Receivable

Alnylam Pharmaceuticals Net product revenues — Accounts Receivable increased by 8.6% to $727.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 133.1%, from $311.93M to $727.20M. Over 4 years (FY 2021 to FY 2025), Net product revenues — Accounts Receivable shows an upward trend with a 46.0% CAGR.

Analysis

StatementSegment
Rolls up toAccounts Receivable
Metric ID: alny_segment_net_product_revenues_accounts_receivable_net

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$112.66M$116.87M$124.90M$132.27M$131.27M$160.16M$203.80M$190.93M$184.16M$198.49M$210.10M$239.98M$248.65M$266.38M$269.90M$311.93M$474.70M$572.80M$669.50M$727.20M
QoQ Change—+3.7%+6.9%+5.9%-0.8%+22.0%+27.2%-6.3%-3.5%+7.8%+5.9%+14.2%+3.6%+7.1%+1.3%+15.6%+52.2%+20.7%+16.9%+8.6%
YoY Change————+16.5%+37.0%+63.2%+44.3%+40.3%+23.9%+3.1%+25.7%+35.0%+34.2%+28.5%+30.0%+90.9%+115.0%+148.1%+133.1%
Range$112.66M – $727.20M
CAGR+48.1%
Avg YoY Growth+54.3%
Median YoY Growth+36.0%
Current Streak11 quarters growth

Frequently Asked Questions

What is Alnylam Pharmaceuticals's net product revenues — accounts receivable?
Alnylam Pharmaceuticals (ALNY) reported net product revenues — accounts receivable of $727.20M in Q1 2026.
How has Alnylam Pharmaceuticals's net product revenues — accounts receivable changed year-over-year?
Alnylam Pharmaceuticals's net product revenues — accounts receivable increased by 133.1% year-over-year, from $311.93M to $727.20M.
What is the long-term trend for Alnylam Pharmaceuticals's net product revenues — accounts receivable?
Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's net product revenues — accounts receivable has grown at a 46.0% compound annual growth rate (CAGR), from $445.94M to $2.03B.